Open-Label, Bridging Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Treatment- Naive and Treatment-Experienced Russian Subjects With Genotype 1 Chronic Hepatitis C.
Phase of Trial: Phase III
Latest Information Update: 05 Feb 2015
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Janssen-Cilag
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Dec 2012 Actual initiation date changed from Dec 2011 to Jan 2012 as reported by ClinicalTrials.gov.
- 27 Apr 2012 Company (Janssen-Cilag) added as trial sponsor as reported by ClinicalTrials.gov.